Item 2.02.
|
Results of Operations and Financial Condition.
|
On March 8, 2019, Aldeyra Therapeutics, Inc. (the Company) issued a press release and is holding a conference call regarding its financial
results for the quarter and year ended December 31, 2018. The press release is furnished as Exhibit 99.1 to this Current Report on Form
8-K
and is incorporated by reference herein.
Various statements to be made during the conference call are forward-looking statements under the securities laws, including, but not limited to,
statements regarding the Companys plans and expectations for its product candidates. In some cases, you can identify forward looking statements by terms such as, but not limited to, may, might, will,
objective, intend, should, could, can, would, expect, believe, anticipate, project, target, design,
estimate, predict, potential, aim, plan or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward-looking statements are based
upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties.
The Company is at an early stage of development
and may not ever have any products that generate significant revenue. All of the Companys development timelines may be subject to adjustment depending on recruitment rate, regulatory review, preclinical and clinical results, and other factors
that could delay the initiation or completion of clinical trials. Important factors that could cause actual results to differ materially from those reflected in the Companys forward-looking statements include, among others, the timing of
enrollment, commencement and completion of the Companys clinical trials, the timing and success of preclinical studies and clinical trials conducted by the Company and its development partners; delay in or